Treatment of Recurrent or Metastatic Uterine Adenosarcoma
Joint Authors
Nathenson, Michael J.
Ravi, Vinod
Conley, Anthony
Lin, Heather
Fleming, Nicole
Source
Issue
Vol. 2017, Issue 2017 (31 Dec. 2017), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2017-12-28
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
Purpose.
This study retrospectively evaluated overall survival (OS) by treatment of recurrent or metastatic uterine adenosarcoma including surgery, radiation, chemotherapy, and hormonal therapy and evaluated OS and progression-free survival (PFS) after 1st line systemic chemotherapy.
Methods.
78 patients with recurrent or metastatic adenosarcoma comprised the study population.
The Kaplan-Meier method was used to estimate OS and PFS.
The log-rank test was performed to test the difference in survival between groups.
Results.
Median OS from diagnosis of recurrent or metastatic disease was 1.8 yrs.
OS was influenced by pathology on recurrence, p=0.035.
Median OS differed by surgery for 1st recurrence 26.3 months versus 15.1 months.
OS was not influenced by chemotherapy, p=0.58, palliative radiation, p=0.58, or hormonal therapy, p=0.15.
The response rate (CR + PR) per RECIST 1.1 for chemotherapy was 31.2% for doxorubicin-based regimens and 14.3% for gemcitabine/docetaxel.
OS since 1st line chemotherapy was not significantly different among chemotherapy regimens.
However, the median PFS was superior for doxorubicin/ifosfamide (15.4 months) compared to gemcitabine/docetaxel (5.0 months), platinum-based regimens (5.7 mo), or other doxorubicin-based regimens (6.5 months).
Conclusion.
These results suggest that surgery is an important treatment modality for recurrent or metastatic uterine adenosarcoma, and the most effective chemotherapeutics are doxorubicin/ifosfamide and gemcitabine/docetaxel.
American Psychological Association (APA)
Nathenson, Michael J.& Conley, Anthony& Lin, Heather& Fleming, Nicole& Ravi, Vinod. 2017. Treatment of Recurrent or Metastatic Uterine Adenosarcoma. Complexity،Vol. 2017, no. 2017, pp.1-9.
https://search.emarefa.net/detail/BIM-1197728
Modern Language Association (MLA)
Nathenson, Michael J.…[et al.]. Treatment of Recurrent or Metastatic Uterine Adenosarcoma. Complexity No. 2017 (2017), pp.1-9.
https://search.emarefa.net/detail/BIM-1197728
American Medical Association (AMA)
Nathenson, Michael J.& Conley, Anthony& Lin, Heather& Fleming, Nicole& Ravi, Vinod. Treatment of Recurrent or Metastatic Uterine Adenosarcoma. Complexity. 2017. Vol. 2017, no. 2017, pp.1-9.
https://search.emarefa.net/detail/BIM-1197728
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1197728